Why is it so hard to design placebo-controlled cannabis trials?

Placebo-controlled trials are the gold standard for establishing efficacy, but cannabis presents unique methodological challenges that make blinding extremely difficult. The core problem: cannabis produces obvious subjective effects (intoxication, altered perception) that allow participants to identify whether they received active drug or placebo — breaking the blind. Solutions attempted: (1) Active placebo: using low-dose THC as placebo — but this introduces a pharmacologically active comparator. (2) Deactivated cannabis: cannabis with THC removed — but participants familiar with cannabis can detect the difference. (3) Expectancy manipulation: telling all participants they may receive active drug — partially addresses expectancy effects. (4) Crossover designs: each participant receives both active and placebo in sequence — increases statistical power but introduces carryover effects. (5) Oral/capsule delivery: reduces sensory cues but doesn't eliminate subjective effects. Additional challenges: Schedule I restrictions limit research supply quality; standardizing dose is difficult; self-reported outcomes are subjective; and the heterogeneity of cannabis products makes replication difficult across studies.